Efficacy and Safety of Low-Level Monochromatic Red-Light for High Myopia Control in Adults

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

60 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-08-01

Study Completion Date

2025-10-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this clinical study is to confirm the effectiveness and safety of low-level monochromatic red-light for high myopia control in adults

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

The Effectiveness and Safety of Low-intensity Single-wavelength Red Light in Controlling High Myopia in Children and Adolescents：A Randomized, Controlled, Multicenter Clinical Trial

NCT05184621

Age 3 to 16 Years (Inclusive), Male or Female Clinical Diagnosis Confirming That Myopia Has Occurred in at Least One Eye The Guardian Voluntarily Signed the Subject's Informed Consent Form

COMPLETED NA

Red Light Intervention on Myopic Progression

NCT05203432

Myopia

UNKNOWN NA

Development of Bioluminescent Myopia Prevention and Control Instrument and Evaluation of Its Effect on Myopia

NCT07208617

Myopia

NOT_YET_RECRUITING NA

Red Light Intervention for Myopia Prevention

NCT04825769

Myopia

COMPLETED NA

Daily Low-level Red Light and 0.01% Low-dose Atropine for Myopia Prevention

NCT06727019

Myopia

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Currently, there is still a lack of effective methods for managing adult high myopia globally. The Elsing Myopia and Amblyopia Therapy Instrument, developed by Suzhou Industrial Park Zuoguan Medical Equipment Co., Ltd., has gained widespread usage in mainland China for amblyopia treatment and myopia control. This instrument utilizes low-intensity laser therapy (LLLT) for treatment, demonstrating improvements in visual acuity without any local or systemic side effects. The low-intensity laser induces photochemical reactions in the retina, such as enhancing cytochrome C oxidase activity, modulating gene expression to regulate the mitochondrial respiratory chain, and increasing the biological activity of nitric oxide. These mechanisms have been applied in the treatment of age-related macular degeneration and diabetic retinopathy. As the onset of myopia is closely linked to retinal signaling pathways, preliminary test data suggests that the instrument can significantly slow down myopia progression. This study aims to investigate the potential of low-intensity laser therapy in preventing and treating high myopia in adults, providing innovative approaches to mitigate the widespread impact of high myopia.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

High Myopia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Low-Level Red-Light threapy plus glasses threapy

Myopic amblyopia comprehensive treatment equipment + conventional optometry with glasses for treatment

Group Type EXPERIMENTAL

Myopic amblyopia comprehensive treatment instrument

Intervention Type DEVICE

Myopic amblyopia comprehensive treatment instrument is produced by Suzhou Industrial Park Zuoguan Medical Equipment Co., LTD.

Glasses

Intervention Type DEVICE

Optometry with glasses as a routine treatment

glasses threapy

conventional optometry with glasses for treatment

Group Type EXPERIMENTAL

Glasses

Intervention Type DEVICE

Optometry with glasses as a routine treatment

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Myopic amblyopia comprehensive treatment instrument

Myopic amblyopia comprehensive treatment instrument is produced by Suzhou Industrial Park Zuoguan Medical Equipment Co., LTD.

Intervention Type DEVICE

Glasses

Optometry with glasses as a routine treatment

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Age between 18 and 40 years, regardless of gender.
2. Presence of myopic refractive error in at least one eye, with myopic lens power after mydriasis exceeding 6.00D, diffusivity less than 2.00D, binocular anisometropia less than 3.00D, and best corrected distance visual acuity of at least 0.6, as well as near visual acuity of at least 0.6.
3. Normal cognitive abilities and language communication skills, capable of actively cooperating with the required treatment.
4. Absence of contraindications for atropine use, such as acute ocular inflammation, dry eye, keratoconus, and diabetes.
5. Written informed consent obtained from the patients.

Exclusion Criteria

1. History of photoallergy, glaucoma, trichiasis syndrome, ocular hypertension, fundus macula lesions, or eye injuries.
2. Corneal curvature examination revealing an average K value of the anterior corneal surface of ≥45.
3. Presence of systemic diseases (e.g., heart, liver, kidney diseases) and congenital hereditary myopia.
4. Chronic eye diseases, including ocular trauma, strabismus, or previous ocular surgery, as well as allergic conjunctivitis.
5. Previous internal trichiasis, severe corneal opacity, conjunctival infection, or other eye diseases.
6. Neurological diseases, allergies, or contraindications to atropine or other therapeutic drugs.
7. Presence of immune system and systemic diseases such as albinism, psoriasis, nephrotic syndrome, systemic lupus erythematosus, or diabetes.
8. Epilepsy or mental disorders that hinder normal communication.
9. Previous use of other treatments to control myopia progression, such as anticholinergic drugs like atropine within the past 3 months, or participation in other studies involving functional frame lenses, multifocal soft lenses, or similar interventions.
10. Any other situation deemed unsuitable for participation in the study by the researcher.

Minimum Eligible Age

18 Years

Maximum Eligible Age

40 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No